Immunotherapy With Nivolumab or Nivolumab Plus Ipilimumab vs. Double Placebo for Stage IV Melanoma w. NED

NCT02523313 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

167

Enrollment

OTHER

Sponsor class

Conditions

Malignant Melanoma

Interventions

DRUG: Nivolumab + Placebo
DRUG: Nivolumab + Ipilimumab
DRUG: Double Placebo Control

Sponsor

Prof. Dr. med. Dirk Schadendorf